Gene amplification as a prognostic factor in primary brain tumors

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Prognosis for primary malignant brain tumors relies on histology, age, and functional status.
• Quantifying molecular markers could potentially improve patient management.
• Epidermal growth factor receptor (EGFR), mouse double minute 2 (MDM2), and cyclin-dependent kinase 4 (CDK4) are key genes in cellular signaling.

Purpose of the Study:

• To measure gene dosage of EGFR, MDM2, and CDK4 in brain tumor specimens.
• To correlate gene amplification status with standard prognostic factors and patient survival.
• To investigate the predictive value of these gene amplifications for survival outcomes.

Main Methods:

• Gene dosage of EGFR, MDM2, and CDK4 was measured using DNA hybridization and quantified by densitometry.
• Amplification was defined as a gene signal at least twice the normal level.
• Survival, age, Karnofsky performance status, and histology were correlated with gene amplification status using statistical analysis, including Cox regression.

Main Results:

• Median survival was 70.7 weeks with any gene amplification versus 88.6 weeks without (P = 0.0369).
• EGFR gene amplification alone showed a median survival of 58.9 weeks compared to 88.6 weeks without (P = 0.0104).
• Cox analysis identified only tumor histology and Karnofsky performance status as significant independent predictors of survival; gene amplification was not predictive (P = 0.8249 for glioblastomas).

Conclusions:

• Gene amplification of EGFR, MDM2, and CDK4 alone was not a significant predictor of survival in primary malignant brain tumors.
• The lack of correlation may be due to these genes being part of larger, complex signaling systems.
• Histology and functional status remain the most reliable prognostic factors for these patients.